Prior Movesmirror the world’s best investors
Preview. Tables on this page show their first five rows. Sign in if you subscribe, or see what Pro includes.

ZBRA: who owns it, and who’s predicted to buy next

Zebra Technologies Corp-Cl A · Industrials · on the Prior Moves forward board for 2026-09-30 at rank #44. Research, not investment advice.

78 PriorScorelast close $388.123m momentum 49.2%

Predicted to buy next quarter

3 tracked investors are included in the model-ranked expectations for ZBRA in 2026-09-30. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.

Strongest ranked investor signal: Stanley Druckenmiller. No calibrated purchase probability is shown.

Currently disclosed holders

From the most recent 13F books we track, 1 investor discloses a position in ZBRA (weight = share of that investor’s US equity book). A 13F can be up to 45 days stale.

InvestorBook weight
Ariel2.4%

Mutual fund and ETF holders

306 US mutual funds and ETFs from 137 fund families reported a position in ZBRA for the quarter ending 2026-06-30. Against their own report a quarter earlier, 78 raised shares, 28 opened a new position, 138 cut and 36 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about ZBRA.

Fund familyFundsShare of fund-held shares
Vanguard Index Funds433.9%
Ishares Trust159.9%
Capitol Series Trust57.8%
John Hancock Funds Iii17.5%
Victory Portfolios54.7%
J.P. Morgan Fleming Mutual Fund Group, Inc.14.2%
Ariel Investment Trust13.0%
Mfs Series Trust Xi12.5%
The weekly digest

The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.

See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-16. Research, not investment advice, see the disclaimer.